Drug intelligence / Profile preview

clarithromycin + rifampicin + ethambutol

Development stage: Unknown
Lead developer: Taisho Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

A three-drug antibiotic regimen consisting of clarithromycin, rifampicin, and ethambutol, primarily used for the treatment of Mycobacterium avium complex (MAC) infections. This combination is recommended by the American Thoracic Society and the Infectious Diseases Society of America as a standard treatment approach for MAC pulmonary disease and other MAC infections. The regimen works through multiple mechanisms to combat mycobacterial infections and is typically administered for extended periods.

Other names: REC

Targets

Bacterial 50S ribosomal subunitrpoB (DNA-directed RNA polymerase subunit beta)AftA (Arabinosyltransferase AftA)

Beyond the preview

Go deeper on clarithromycin + rifampicin + ethambutol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clarithromycin + rifampicin + ethambutol.

Explore the full profile